Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997971 | 0.93 | CA1 (0.44) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL14997649 | 0.90 | CA12 (0.40) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL2841787 | 0.88 | MCHR1 (0.39) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL11138066 | 0.87 | CA12 (0.42) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL8370835 | 0.85 | CA12 (0.41) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL10731624 | 0.85 | MCHR1 (0.43) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL1603835 | 0.83 | GAA (0.41) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL30406323 | 0.83 | CA12 (0.41) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL11759385 | 0.83 | CA12 (0.41) | CA12CA1CA9STAT3ALDH1A1 | |
| SCHEMBL9672034 | 0.83 | CA12 (0.47) | CA12CA1CA9STAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545666-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20220363672-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| US-11028078-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20160264556-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | UNIV JOHNS HOPKINS (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346791-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| EP-2799427-A1 | Therapeutic compounds | Fibrotech Therapeutics PTY LTD (AU) | 2014-11-05 | — | — | EP | disclosed |
| US-20140221393-A1 | Itraconazole Analogs and Use Thereof | THE JOHNS HOPKINS UNIVERSITY | 2014-08-07 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013036866-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | CA12 2889/4885CA1 4232/4885CA9 1511/4885 |
| US-20220363672-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | CA12 2304/4885CA1 4584/4885CA9 3162/4885 |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | CA12 2304/4885CA1 4584/4885CA9 3162/4885 |
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | CA12 2879/4885CA1 4202/4885CA9 1651/4885 |
| US-20160264556-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | CA12 2304/4885CA1 4584/4885CA9 3162/4885 |
| US-12545666-B2 | Itraconazole analogs and use thereof | SHH, SMO, GLI1 | CA12 132/4885CA1 2124/4885CA9 595/4885 |
| US-11028078-B2 | Itraconazole analogs and use thereof | SHH, GLI1, KDR | CA12 2304/4885CA1 4584/4885CA9 3162/4885 |
| US-20140221393-A1 | Itraconazole Analogs and Use Thereof | SHH, GLI1, KDR | CA12 2304/4885CA1 4584/4885CA9 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.